Significant delay in the introduction of systemic treatment of moderate to severe psoriasis: A prospective multicentre observational study in outpatients from hospital dermatology departments in France

British Journal of Dermatology

Volumn 167, Issue 3, 2012, Pages 643-648

  Maza, A ^a   Richard, M A ^b   Aubin, F ^c   Ortonne, J P ^d   Prey, S ^e   Bachelez, H ^f   Beylot Barry, M ^e   Bulai Livideanu, C ^a   Lahfa, M ^a   Nougue J ^g   Mengual, X ^h   Le Moigne, M ^a   Lauwers Cances, V ⁱ   Paul, C ^a  

^a France   (France)

^b University of the Mediterranean Aix Marseille II   (France)

^c UNIVERSITÉ DE FRANCHE COMTÉ   (France)

^d CENTRE HOSPITALIER UNIVERSITAIRE DE NICE   (France)

^e BORDEAUX UNIVERSITY HOSPITAL   (France)

^f SAINT LOUIS HOSPITAL   (France)

^g Centre Hospitalier de Montauban   (France)

^h Statitec   (France)

ⁱ TOULOUSE UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BETAMETHASONE DIPROPIONATE PLUS CALCIPOTRIOL; RETINOID DERIVATIVE; STEROID; VITAMIN D DERIVATIVE;

ADULT; ARTICLE; CONFIDENCE INTERVAL; DERMATOLOGY LIFE QUALITY INDEX; DISEASE CONTROL; DISEASE COURSE; DISEASE SEVERITY; FEMALE; FRANCE; HEALTH CARE PLANNING; HOSPITAL ANXIETY AND DEPRESSION SCALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL DECISION MAKING; MULTICENTER STUDY; NAIL PSORIASIS; OBSERVATIONAL STUDY; OUTPATIENT DEPARTMENT; PHOTOCHEMOTHERAPY; PHYSICIAN; PRIORITY JOURNAL; PROSPECTIVE STUDY; PSORIASIS; PSORIASIS AREA AND SEVERITY INDEX; PSORIASIS VULGARIS; PSORIATIC ARTHRITIS; QUESTIONNAIRE; RATING SCALE; RISK; THERAPY DELAY; TREATMENT OUTCOME;

AMBULATORY CARE; DERMATOLOGIC AGENTS; FEMALE; FRANCE; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROSPECTIVE STUDIES; PSORIASIS; TIME-TO-TREATMENT; TREATMENT OUTCOME;

EID: 84865593732     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2012.10991.x     Document Type: Article

References (21)

1. Christophers E,. Psoriasis. Epidemiology and clinical spectrum. Clin Exp Dermatol 2001; 26: 314-20.
2. Rapp SR, Feldman SR, Exum ML, et al. Psoriasis causes as much disability as other major medical diseases. J Am Acad Dermatol 1999; 41: 401-7. (Pubitemid 29418506)
3. Finzi A, Colombo D, Caputo A, et al. Psychological distress and coping strategies in patients with psoriasis: The PSYCHAE study. J Eur Aca Dermatol 2007; 21: 1161-9. (Pubitemid 47423402)
4. Paul C, Gourraud PA, Bronsard V, et al. Evidence-based recommendations to assess psoriasis severity: systematic literature review and expert opinion of a panel of dermatologists. J Eur Acad Dermatol Venereol 2010; 24 (Suppl. 2): 2-9.
5. Krueger G, Koo J, Lebwohl M, et al. The impact of psoriasis on quality of life: results of a 1998 National Psoriasis Foundation patient-membership survey. Arch Dermatol 2001; 137: 280-4. (Pubitemid 32240779)
6. Dubertret L, Mrowietz U, Ranki A, et al. European patient perspectives on the impact of psoriasis: the EUROPSO patient membership survey. Br J Dermatol 2006; 155: 729-36. (Pubitemid 44352553)
7. Stern RS, Nijsten T, Feldman SR, et al. Psoriasis is common, carries a substantial burden even when not extensive, and is associated with widespread treatment dissatisfaction. J Investig Dermatol Symp Proc 2004; 9: 136-9. (Pubitemid 38457271)
8. Poulin Y, Papp KA, Wasel NR, et al. A Canadian online survey to evaluate awareness and treatment satisfaction in individuals with moderate to severe plaque psoriasis. Int J Dermatol 2010; 49: 1368-75.
9. Gardinal I, Ammoury A, Paul C,. Moderate to severe psoriasis: from topical to biological treatment. J Eur Acad Dermatol 2009; 23: 1324-6.
10. Richards HL, Fortune DG, Griffiths CE, Main CJ,. Alexithymia in patients with psoriasis: clinical correlates and psychometric properties of the Toronto Alexithymia Scale-20. J Psychosom Res 2005; 58: 89-96. (Pubitemid 40354347)
11. Masmoudi J, Maalej I, Masmoudi A, et al. [Alexithymia and psoriasis: a case-control study of 53 patients]. Encephale 2009; 35: 10-17, [in French].
12. Chugg K, Barton C, Antic R, et al. The impact of alexithymia on asthma patient management and communication with health care providers: a pilot study. J Asthma 2009; 46: 126-9.
13. Housiaux M, Luminet O, Van Broeck N, Dorchy H,. Alexithymia is associated with glycaemic control of children with type 1 diabetes. Diabetes Metab 2010; 1: 455-62.
14. Gönül M, Gül U, Cakmak SK, et al. Unconventional medicine in dermatology outpatients in Turkey. Int J Dermatol 2009; 48: 639-44.
15. Strowd LC, Yentzer BA, Fleischer AB Jr, et al. Increasing use of more potent treatment for psoriasis. J Am Acad Dermatol 2009; 60: 478-81.
16. Meyer N, Paul C, Feneron D, et al. Psoriasis: an epidemiological evaluation of disease burden in 590 patients. J Eur Acad Dermatol Venereol 2010; 24: 1075-82.
17. Kragballe K, Noerrelund KL, Lui H, et al. Efficacy of once-daily treatment regimens with calcipotriol/betamethasone dipropionate ointment and calcipotriol ointment in psoriasis vulgaris. Br J Dermatol 2004; 150: 1167-73. (Pubitemid 38932288)
18. Menter A, Tyring SK, Gordon K, et al. Adalimumab therapy for moderate to severe psoriasis: a randomized, controlled phase III trial. J Am Acad Dermatol 2008; 58: 106-15. (Pubitemid 350298146)
19. Tyring S, Gottlieb A, Papp K, et al. Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trial. Lancet 2006; 367: 29-35. (Pubitemid 43038667)
20. Langley RG, Feldman SR, Han C, et al. Ustekinumab significantly improves symptoms of anxiety, depression, and skin-related quality of life in patients with moderate-to-severe psoriasis: results from a randomized, double-blind, placebo-controlled phase III trial. J Am Acad Dermatol 2010; 63: 457-65.
21. Thaçi D, Ortonne JP, Chimenti S, et al. A phase IIIb, multicentre, randomized, double-blind, vehicle-controlled study of the efficacy and safety of adalimumab with and without calcipotriol/betamethasone topical treatment in patients with moderate to severe psoriasis: the BELIEVE study. Br J Dermatol 2010; 163: 402-11.